Evidence map›Paper›PMID 25538405›Full record

ArticleIndian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology2014

Thiopurine methyltransferase polymorphisms in children with acute lymphoblastic leukemia.

Vijay Gandhi Linga, Dorra Babu Patchva, Krishna Mohan Mallavarapu, Venkata Tulasi, Krishnamani Iyer Kalpathi, Ashok Pillai, Sadashivudu Gundeti, Senthil J Rajappa, Raghunadharao Digumarti

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Pharmacogenomics and personalized medicine · 2021
    Article
  4. Meta-analysis of the impact of thioprineOncoTargets and therapy · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Vijay Gandhi LingaDepartment of Medical Oncology, Nizams Institute of Medical Science, Hyderabad, Telangana, India.
Dorra Babu PatchvaDepartment of Pharmacology, Apollo Institute of Medical Science and Reasearch, Hyderabad, Telangana, India.
Krishna Mohan MallavarapuDepartment of Medical Oncology, Nizams Institute of Medical Science, Hyderabad, Telangana, India.
Venkata TulasiDepartment of Medical Oncology, Basavatarakam Indo American Cancer Institute and Research, Hyderabad, Telangana, India.
Krishnamani Iyer KalpathiDepartment of Medical Oncology, Nizams Institute of Medical Science, Hyderabad, Telangana, India.
Ashok PillaiDepartment of Medical Oncology, Nizams Institute of Medical Science, Hyderabad, Telangana, India.
Sadashivudu GundetiDepartment of Medical Oncology, Nizams Institute of Medical Science, Hyderabad, Telangana, India.
Senthil J RajappaDepartment of Medical Oncology, Basavatarakam Indo American Cancer Institute and Research, Hyderabad, Telangana, India.
Raghunadharao DigumartiDirector and Head, Department of Medical Oncology, Tata Memorial Hospital, Aganampudi, Vishakapatnam, Andra Pradesh, India.
Nizam's Institute of Medical Sciences · INBasavatarakam Indo American Cancer Hospital and Research Institute · INTata Memorial Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcute lymphoblastic leukemia (ALL) is the most common malignancy in children. 6-mercaptopurine (6-MP) and methotrexate are backbone drugs for maintenance phase of treatment. Purine Analogs 6-MP/6-thioguanine/azathiopurine are metabolized to its inactive form by the enzyme thiopurine methyltransferase (TPMT). Ninety percent of the population harbor wild type on both alleles (TPMT wild/wild), 10% are heterozygous, that is, one allele is mutant (TPMT wild/mutant) and 0.3% are homozygous, that is, both allele are mutant (TPMT mutant/mutant). In heterozygous and homozygous variant, activity of enzyme is low, leading to a higher incidence of toxicity (myelosuppression).

aimThe primary objective was to access the polymorphism of the enzyme, TPMT, in Children with ALL. Secondary objective was to correlate TPMT genotype with 6-MP toxicities. MATERIALS AND

methodsSeventy-two children with newly diagnosed ALL during first maintenance phase were serially enrolled after obtaining consent. Five ml of peripheral blood was drawn and DNA extracted. TPMT 2 polymorphisms were performed using Allele specific polymerase chain reaction (PCR) and TPMT 3B and 3C are performed by PCR-restriction fragment length polymorphism.

resultsSixty-nine children of 72 (95.8%) were wild for TPMT polymorphism and 3 (4.2%) were heterozygous for TPMT. Among the heterozygous variant one each (33.3%) were heterozygous for 2A, 3A, 3C. Febrile neutropenia was the most common toxicity in both wild and heterozygous group.

conclusionThe frequency of TPMT polymorphisms in children with ALL is 4.2%. Heterozygous variant is this study are one each (33%) of 2A, 3A, 3C.

Indexed as

Acute lymphoblastic leukemiamyelosuppressionthiopurine methyltransferase

Identifiers

PMID25538405
PMCPMC4264274
OpenAlexW2095254453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.